Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 60
Filtrar
1.
J Thromb Haemost ; 6(9): 1558-64, 2008 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-18624980

RESUMEN

OBJECTIVE: To assess the antithrombotic and profibrinolytic effects of tiplaxtinin (PAI-039), an orally bioavailable antagonist of PAI-1, in rat models of thrombosis. METHODS AND RESULTS: Carotid artery and vena cava vascular injury was produced by application of FeCl3 and blood flow was monitored using ultrasonic technology. To assess efficacy in a thrombosis prevention paradigm, PAI-039 was administered orally 90 min before injury (1-30 mg kg(-1)). To assess efficacy in a thrombosis treatment paradigm, vascular injury and stable thrombus formation were followed 4 h later by recovery and PAI-039 administration. PAI-039 prevented carotid artery occlusion in 20, 68 and 60% of animals pretreated with 0.3, 1.0 and 3.0 mg kg(-1), respectively. Time to occlusive thrombosis was increased from 18.2 +/- 4.6 min in controls to 32.5 +/- 8.7 (P = ns), 46.1 +/- 7.0 (P < 0.05), and 41.6 +/- 11.3 min (P < 0.05) in the respective PAI-039 treatment groups. In the vena cava protocol, PAI-039 pretreatment significantly reduced thrombus weight at PAI-039 doses of 3, 10 and 30 mg kg(-1). When PAI-039 was dosed in a treatment paradigm 4 h after stable arterial and venous thrombosis, a significant reduction in thrombus weight was observed 24 h later at PAI-039 doses of 3, 10 and 30 mg kg(-1). PAI-039 (10, 30 and 100 mg kg(-1)) had no effect on platelet aggregation in response to ADP or collagen and was not associated with increased bleeding or prolonged prothrombin time. In animals bearing no vascular injury, PAI-039 had no effect on circulating, low-levels of PAI-1 activity. In contrast, circulating PAI-1 activity increased 5-fold following the induction of vascular injury, which was completely neutralized by PAI-039. CONCLUSIONS: PAI-039 exerts antithrombotic efficacy in rat models of arterial and venous vascular injury without effecting platelet aggregation.


Asunto(s)
Ácidos Indolacéticos/farmacología , Inhibidor 1 de Activador Plasminogénico , Trombosis/prevención & control , Administración Oral , Animales , Disponibilidad Biológica , Modelos Animales de Enfermedad , Ácidos Indolacéticos/administración & dosificación , Ácidos Indolacéticos/farmacocinética , Masculino , Agregación Plaquetaria/efectos de los fármacos , Tiempo de Protrombina , Ratas , Ratas Sprague-Dawley
4.
J Am Acad Child Adolesc Psychiatry ; 40(8): 973-6, 2001 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-11501698

RESUMEN

We have provided an overview of techniques used to assess variables in the applied behavioral sciences. Most of the methods are used by both quantitative/positivist and qualitative/constructivist researchers but to different extents. Qualitative researchers prefer more open-ended, less structured data collection techniques than do quantitative researchers. Direct observation of participants is common in experimental and qualitative research; it is less common in so-called survey research, which tends to use self-report questionnaires. It is important that investigators use instruments that are reliable and valid for the population and purpose for which they will be used. Standardized instruments have manuals that provide norms and indexes of reliability and validity. However, if the populations and purpose on which these data are based are different from yours, it may be necessary for you to develop your own instrument or provide new evidence of reliability and validity.


Asunto(s)
Recolección de Datos/métodos , Experimentación Humana , Recolección de Datos/normas , Humanos , Variaciones Dependientes del Observador , Escalas de Valoración Psiquiátrica , Pruebas Psicológicas , Autorrevelación , Encuestas y Cuestionarios
17.
J Am Acad Child Adolesc Psychiatry ; 38(12): 1595-7, 1999 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-10596261
19.
J Clin Endocrinol Metab ; 84(9): 3222-7, 1999 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-10487691

RESUMEN

To further investigate the role of plasminogen activator inhibitor-1 (PAI-1) in adipose tissue physiology, the production and regulation of PAI-1 was determined in primary cultures of human preadipocytes. When expressed as production per cell and cultured under identical conditions, human preadipocytes from both visceral (omental) and sc depots of lean and obese individuals released significant, yet similar, amounts of PAI-1 protein into the conditioned medium. High steady-state PAI-1 messenger RNA (mRNA) concentrations were observed in visceral and sc preadipocytes, with the relative level of expression equivalent to beta-actin mRNA. Tumor necrosis factor alpha significantly decreased PAI-1 production in a concentration-dependent manner in both visceral and sc cultures, whereas transforming growth factor beta significantly elevated PAI-1 production, but only in sc preadipocytes from obese individuals. Addition of insulin had no effect on antigen levels in conditioned medium of preadipocyte cultures. Stimulation of the preadipocyte cultures with a defined medium resulted in differentiation to the adipocyte phenotype, as determined by flow cytometric analysis, verifying the cultures as human preadipocyte. These studies are the first to observe significant PAI-1 mRNA expression and protein production in primary cultures of a human adipose tissue cellular component, and they suggest that nascent adipocytes contribute significantly to the elevated plasma PAI-1 observed in obesity.


Asunto(s)
Adipocitos/metabolismo , Inhibidor 1 de Activador Plasminogénico/biosíntesis , Inhibidor 1 de Activador Plasminogénico/metabolismo , Células Madre/metabolismo , Actinas/genética , Adipocitos/efectos de los fármacos , Recuento de Células , Diferenciación Celular , Células Cultivadas , Medios de Cultivo Condicionados , Expresión Génica , Humanos , Insulina/farmacología , Inhibidor 1 de Activador Plasminogénico/genética , ARN Mensajero/análisis , Células Madre/efectos de los fármacos , Factor de Crecimiento Transformador beta/farmacología , Factor de Necrosis Tumoral alfa/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA